RT Journal Article
T1 Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.
A1 van Gelder, M
A1 de Wreede, L C
A1 Bornhäuser, M
A1 Niederwieser, D
A1 Karas, M
A1 Anderson, N S
A1 Gramatzki, M
A1 Dreger, P
A1 Michallet, M
A1 Petersen, E
A1 Bunjes, D
A1 Potter, M
A1 Beelen, D
A1 Cornelissen, J J
A1 Yakoub-Agha, I
A1 Russell, N H
A1 Finke, J
A1 Schoemans, H
A1 Vitek, A
A1 Urbano-Ispízua, Á
A1 Blaise, D
A1 Volin, L
A1 Chevallier, P
A1 Caballero, D
A1 Putter, H
A1 van Biezen, A
A1 Henseler, A
A1 Schönland, S
A1 Kröger, N
A1 Schetelig, J
AB Even with the availability of targeted drugs, allogeneic hematopoietic cell transplantation (allo-HCT) is the only therapy with curative potential for patients with CLL. Cure can be assessed by comparing long-term survival of patients to the matched general population. Using data from 2589 patients who received allo-HCT between 2000 and 2010, we used landmark analyses and methods from relative survival analysis to calculate excess mortality compared with an age-, sex- and calendar year-matched general population. Estimated event-free survival, overall survival and non-relapse mortality (NRM) 10 years after allo-HCT were 28% (95% confidence interval (CI), 25-31), 35% (95% CI, 32-38) and 40% (95% CI, 37-42), respectively. Patients who passed the 5-year landmark event-free survival (N=394) had a 79% probability (95% CI, 73-85) of surviving the subsequent 5 years without an event. Relapse and NRM contributed equally to treatment failure. Five-year mortality for 45- and 65-year-old reference patients who were event-free at the 5-year landmark was 8% and 47% compared with 3% and 14% in the matched general population, respectively. The prospect of long-term disease-free survival remains an argument to consider allo-HCT for young patients with high-risk CLL, and programs to understand and prevent late causes of failure for long-term survivors are warranted, especially for older patients.
YR 2016
FD 2016-12-12
LK https://hdl.handle.net/10668/25107
UL https://hdl.handle.net/10668/25107
LA en
DS RISalud
RD Apr 6, 2025